// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure

Ahmed Ghoneem - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Amyloidosis, transthyretin-related

Tafamidis meglumine

COMPARISON OF STANDARDIZED TREATMENT EFFECT SIZES FOR INVASIVE AND NON-INVASIVE ENDPOINTS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM THE REPAIR STUDY

David G. Kiely - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

macitentan

STATINS REDUCE PLAQUE STRUCTURAL STRESS THROUGH REMODELING ARTERY GEOMETRY AND PLAQUE ARCHITECTURE

Sophie Gu - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Atorvastatin

SEX DIFFERENCES IN DISTRIBUTION, MANAGEMENT AND OUTCOMES OF COMBINED ISCHEMIC-BLEEDING RISK FOLLOWING ACUTE CORONARY SYNDROME

Mohamed Mohamed - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

DETERMINING THE MECHANISM OF MYOCARDIAL INJURY AND ROLE OF CORONARY ARTERY DISEASE IN TYPE 2 MYOCARDIAL INFARCTION (DEMAND-MI)

Andrew R. Chapman - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left ventricular dysfunction

N/A

FUNCTIONAL TESTING FOR INDUCIBLE MYOCARDIAL ISCHAEMIA: A WASTE OF TIME AND RESOURCES IN RENAL TRANSPLANT CANDIDATES?

Baskar Sekar - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dobutamine

EPICARDIAL AND MICROVASCULAR DYSFUNCTION WITH FRACTIONAL FLOW RESERVE AND INSTANTANEOUS WAVE-FREE RATIO DIAGNOSIS IN FLOW-LIMITING CORONARY ARTERIES FROM IDEAL AND DEFINE-FLOW

Yuetsu Kikuta - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Microvascular dysfunction

N/A

THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION

Paul J. Cacciottolo - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Alirocumab

AIR POLLUTION AND ADVERSE CARDIAC REMODELLING IN PATIENTS WITH DILATED CARDIOMYOPATHY

Upasana Tayal - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

REVIEWING MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION WITH EMERGING THERAPIES AN ONLINE EDUCATIONAL INTERVENTION

Sarah Mendly - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

N/A

USE OF SODIUM ZIRCONIUM CYCLOSILICATE FOR UP-TITRATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR THERAPY IN PATIENTS WITH HEART FAILURE: A CASE SERIES

Rhys Williams - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Sodium zirconium cyclosilicate

DISPROPORTIONATE MITRAL REGURGITATION DETERMINES SURVIVAL IN ACUTE HEART FAILURE

Berrill Max - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mitral valve regurgitation

N/A

UPGRADING TO CARDIAC RESYNCHRONISATION THERAPY: CONCORDANCE OF REAL WORLD EXPERIENCE WITH CLINICAL GUIDELINES

Laura Tan - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CHANGING INCIDENCE AND PROCEDURE COMPLEXITY OF CORONARY ARTERY PERFORATIONS. - A 10-YEAR DATASET

Hamza Umar - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PROSPECTIVE HEALTH RELATED QUALITY OF LIFE ASSESSMENT IN PATIENTS UNDERGOING TRANS-CATHETER AORTIC VALVE IMPLANTATION USING MACNEW QUESTIONNAIRE

Hesham K. Abdelaziz - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A COMPARISON OF THE TRANSRADIAL AND TRANSFEMORAL APPROACHES AMONG POST CORONARY ARTERY BYPASS GRAFT PATIENTS UNDERGOING ANGIOGRAPHY AND INTERVENTION

Muhammad Jahangir Iftikhar - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

MULTINATIONAL SURVEY ON MANAGEMENT OF PATIENTS WITH PATENT FORAMEN OVALE AND LEFT CIRCULATION THROMBOEMBOLISM

Maciej Debski - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Atrial septal defect

N/A

18F-SODIUM FLUORIDE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY IN ACUTE AORTIC SYNDROME

Maaz J. Syed - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Acclean Plus

ATRIAL UPTAKE ON 99MTC-PYP SCAN IS A NOVEL IMAGING FINDING ASSOCIATED HIGHER RATES OF ATRIAL FIBRILLATION IN PATIENTS WITH OR WITHOUT ATTR CARDIAC AMYLOIDOSIS

Muzna Hussain - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

ATTR amyloidosis

N/A

ROLE OF 4D STRAIN IN ASSESSING RIGHT VENTRICLE SEGMENTS IN ACUTE PULMONARY EMBOLISM

Punit Bedi - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary embolism

N/A

Copyright © 2026. QuantiNova All rights reserved